Siegfried Holding AG

Siegfried Holding AG is a globally leading contract development and manufacturing organization (CDMO) headquartered in Zofingen, Switzerland, founded in 1873. The company specializes in providing integrated services for the pharmaceutical and biotechnology industries, including the development and production of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms such as steriles, ophthalmics, inhalation products, oral solids, and viral vectors. Operating 13 production facilities across seven countries on three continents—including Switzerland, the USA, Germany, Spain, France, Malta, and China—Siegfried supports clients from early-phase drug development through commercial-scale manufacturing, process optimization, registration, packaging, and logistics. With approximately 3,800 employees and revenue exceeding $1.4 billion in 2024, it supplies around 200 of the 1,500 FDA-approved APIs and serves over 500 customers worldwide, contributing to products reaching up to one billion people annually, including over 100 million doses of COVID-19 vaccines. Siegfried emphasizes sustainable practices, holding an AA rating from MSCI and membership in the Dow Jones Best-In-Class Europe Index, while expanding into high-growth areas like cell and gene therapy via its Dinamiqs facility. As a key player in pharmaceuticals, biotechnology, life sciences, and diagnostics, Siegfried Holding AG plays a vital role in scaling innovations to deliver safe drugs globally.